Boehringer Ingelheim Joins Scleroderma Research Foundation’s Conquest Trial Platform
Pharma company is the second to join the project.
The Scleroderma Research Foundation (SRF) announced that Boehringer Ingelheim will contribute an experimental agent to Conquest, one of its clinical trial programs. According to the company, the platform is specifically designed to efficiently advance promising treatments for scleroderma and to nominate agents that should progress from Phase IIb to Phase III clinical trials. Boehringer Ingelheim becomes the second company to contribute to the project after Sanofi was brought on in August.
"Boehringer Ingelheim has a rich history of innovation in the Interstitial Lung Disease (ILD) arena and is bringing their considerable experience and expertise to Conquest,” said Luke Envin, PhD, chairman of the Scleroderma Research Foundation, in a company press release. “The addition of a second deeply committed and highly sophisticated partner to Conquest is a strong validation of the platform's promise and value. Finally, with two partners, Conquest is fully subscribed and fully funded, ensuring that the platform will be able to execute against the vision of building a global community tuned to rapid and efficient clinical development of promising novel therapeutic agents for the high unmet needs of our scleroderma patients."
Reference: The Scleroderma Research Foundation (SRF) Announces Second Partnership for Conquest Trial Platform. PR Newswire. October 3, 2023. Accessed October 6, 2023. https://www.prnewswire.com/news-releases/the-scleroderma-research-foundation-srf-announces-second-partnership-for-conquest-trial-platform-301945702.html
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
